M Lukac
Janssen Pharmaceutica
15 Papers
7 Citations
M Lukac is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Abiraterone acetate & Enzalutamide. The author has an hindex of 4, co-authored 11 publications. Previous affiliations of M Lukac include PAREXEL & Slovak Medical University.
Chat about Author
Papers
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Simon Chowdhury,Anders Bjartell,Nicolaas Lumen,Pablo Maroto,Thomas Paiss,Francisco Gomez-Veiga,Alison Birtle,Gero Kramer,Ewa Kalinka,Dominique Spaeth,Susan Feyerabend,Vsevolod Matveev,Florence Lefresne,M Lukac,Robert Wapenaar,Luis Costa +15 more
TL;DR: This analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in Patients with visceral metastases.
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
Antoine Thiery-Vuillemin,Mads Hvid Poulsen,Edouard Lagneau,Guillaume Ploussard,A. Birtle,Louis Marie Dourthe,Dominique Beal-Ardisson,Elias Pintus,Redas Trepiakas,Laurent Antoni,M Lukac,Suzy Van Sanden,Geneviève Pissart,Alison Reid +13 more
- 01 Aug 2018
TL;DR: This analysis suggests more favourable outcomes with AAP versus ENZ for cognition and fatigue in the first 3 months of treatment initiation for mCRPC.
39
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Martin Boegemann,S. Khaksar,Guillaume Bera,Alison Birtle,Catherine Dopchie,Louis-Marie Dourthe,Els Everaert,Martin Hatzinger,Dirko Hercher,Werner Hilgers,Geoffrey Matus,Laura Garcia Alvarez,Laurent Antoni,M Lukac,Geneviève Pissart,Paul Robinson,Tony Elliott +16 more
TL;DR: Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population, and patients with longer duration of response to ADT presented longer TTF and longer time to progression.
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
Anders Bjartell,Luis Costa,Gero Kramer,B. Zurawski,Luca Galli,Patrick Werbrouck,T. Ecke,Omi Parikh,Mostefa Bennamoun,Camilo García Freire,Avivit Peer,Börje Ljungberg,Irfan Cicin,Emma J. Smith,M Lukac,Robert Wapenaar,Simon Chowdhury +16 more
TL;DR: A prospective, non-interventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted as discussed by the authors .
9
Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
David C. Fajgenbaum,Sheila K Pierson,Dustin Shilling,Cooper Gardner,Amy Y. Liu,Jasira Ziglar,Shawnee Bernstein,Sarah Mann,Jeremy Zuckerberg,M Lukac,Raj Jayanthan,Mary Guilfoyle,Craig Tendler,Jason R. Ruth,Thomas S. Uldrick,Frits van Rhee +15 more
TL;DR: A greater number of clinical and laboratory abnormalities were observed in iMCD patients compared to UCD patients, and a unique two-armed approach to enroll individuals, who have had a lymph node pathology report suggesting "Castleman disease."
6